WEO CRC SC Meeting. Barcelona, Spain October 23, 2015

Size: px
Start display at page:

Download "WEO CRC SC Meeting. Barcelona, Spain October 23, 2015"

Transcription

1 WEO CRC SC Meeting Barcelona, Spain October 23, 2015

2 THE HEMOGLOBIN CONCENTRATION IN A NEGATIVE RESULT AS A PREDICTOR FOR ADVANCED NEOPLASIA Isabel Portillo, Eunare Arana-Arri, Isabel Idigoras, Lorea Martínez-Indart. Colorectal Cancer Screening Programme. Basque Country. mariaisabel.portillovillares@osakidetza.eus

3 No conflicts of interest

4 THE BASQUE COUNTRY PROGRAMME Coverage Objective: To decrease CRC incidence and mortality by detection and treatment of premalignant and malignant lesions First round Second round Third round

5 THE BASQUE COUNTRY PROGRAMME STRATEGY POPULATION BASED year-olds (586,700 people) FIT biennial. Cut-off 20µg Hb/g OC-Sensor from 2010 Colonoscopy under sedation as confirmatory test Information system linked with medical database and cancer registries Primary Care Involved Centralized coordination MAIN RESULTS TOTAL INVITED 958,450 PARTICIPATION RATE 68.5% POSITIVE RATE 6.2% COLONOSCOPY UPTAKE 93.7% CCR DETECTION RATE 3.4 AA DETECTION RATE 23.3 AN DETECTION RATE 26.7 PPV CCR 5.4% PPV AA 37.5% PPV AN 42.9%

6 HYPOTHESIS There is a relationship between the Hb concentration in negative cases and lesion detected in successive rounds A pattern of bleeding could predict the lesion detected after a negative result in successive rounds

7 OBJECTIVES To know the association between Hb concentration in positives cases with an Advanced Neoplasia detected and their previous negative results. To know the pattern of this association by sex, age group, type of lesion compared with no adenomatous lesion. To know the pattern of this association in CRC by localization and stage.

8 METHODS 2 GROUPS 1. Participants who had three rounds with two previous negative results and a lesion detected in the third round 2. Participants who had a previous negative result and a lesion detected in successive round Lesions: Colorectal Cancer, Advanced Adenoma, Advanced Neoplasia (CRC+AA) and Low Risk Adenoma. No lesions: negative FIT and positive FIT and negative colonoscopy for CRC, adenoma or other bleeding colonic pathology. Faecal Hb concentrations differences between lesion detected and previous negative result were analyzed (Mann-Whitney test) Logistic regression: to analyze the association of Hb concentration with the diagnosis of Advanced Neoplasia

9 LIMITATIONS Previous lesion before the debut as positive cases are unknown (only in positive cases the colonoscopy was performed) Comparison in irregular attendees was not analyzed Other risk factors such as lifestyle, morbidity and deprivation were not taken into consideration for this study

10 µg Hb/g µg Hb/g MAIN RESULTS GROUP 1 GROUP 2 First Round 45,185 NEGATIVE FIT Previous Round 178,307 NEGATIVE FIT Second Round Third Round 45,185 NEGATIVE FIT POSITIVE FIT 43,016 NEGATIVE FIT Second Round 10,772 POSITIVE FIT 167,535 NEGATIVE FIT 72 CRC 654 AA 726 AN 367 LRA 911 NEGATIVE COLONOSCOPY 417 CRC 3,260 AA 3,677 AN 1,799 LRA 3,640 NEGATIVE COLONOSCOPY RISK OF A COLONIC ADENOMA/CRC AFTER A PREVIOUS NEGATIVE RESULT Interval of 4 years Interval of 2 years CRC AA AN LRA Group 1 CRC AA AN LRA Group 2

11 µd Hb/g µd Hb/g µd Hb/g GROUP 1: DIFFERENCES IN HB CONCENTRATION BETWEEN THIRD ROUND AND FIRST ROUND BY LESION BOTH SEX Round 1 (µg Hb/g) Round 3-Round 1 (µg Hb/g) LESIONS IN ROUND 3 CRC (72) < <0.001 AA (654) < <0.001 AN (726) < <0.001 LRA (367) < <0.001 NO LESIONS IN ROUND 3 (43,733) TRENDS IN HB CONCENTRATION BY LESION CRC no in 3 round CRC yes in 3 round AA no in 3 round AA yes in 3 round AN no in 3 round AN yes in 3 round round 1 round 2 round 3 round 1 round 2 round 3 round 1 round 2 round 3

12 µd Hb/g µd Hb/g GROUP 1: DIFFERENCES IN HB CONCENTRATION BETWEEN THIRD ROUND AND FIRST ROUND BY LESION WOMEN Round 1 (µg Hb/g) Round 3-Round 1 (µg Hb/g) MEN Round 1 (µg Hb/g) Round 3-Round 1 (µg Hb/g) LESIONS IN ROUND 3 NO LESIONS IN ROUND 3 (24,995) CRC (27) AA (217) AN (244) LRA (149) < < < < < < < LESIONS IN ROUND 3 CRC (45) AA (437) AN (482) LRA (218) NO LESIONS IN ROUND 3 (18,738) < < < < < < < < TRENDS IN HB CONCENTRATION IN ADVANCED NEOPLASIA WOMEN AN no in 3 round AN yes in 3 round MEN AN no in 3 round AN yes in 3 round round 1 round 2 round 3 round 1 round 2 round 3

13 GROUP 1: HB CONCENTRATION BY RANGES IN FIRST ROUND P< P< P< BOTH SEX HB (µg Hb/g) IN ROUND LESIONS IN CRC (72) 84.7% 6.9% 6 8.3% ROUND 3 AA (647) 72.5% 15.5% 12.1% AN (719) 73.7% 14.6% 11.7% LR (364) 83.8% 7.1% 9.1% NO LESIONS IN ROUND 3 (43,652) 94.3% 3.5% 2.3% WOMEN HB (µg Hb/g) IN ROUND LESIONS IN CRC (27) 85.2% 7.4% 7.4% ROUND 3 AA (214) 72.9% 15.4% 11.7% AN (241) 74.3% 14.5% 11.2% LR (149) 86.6% 7.4% 6.0% NO LESIONS IN ROUND 3 (24,948) 95.1% 3.0% 1.9% MEN HB (µg Hb/g) IN ROUND LESIONS IN CRC (45) 84.4% 6.7% 8.9% ROUND 3 AA (433) 72.3% 15.5% 12.2% AN (478) 73.4% 14.6% 11.9% LR (215) 81.9% 7.0% 11.2% NO LESIONS IN ROUND 3 (18,704) 93.3% 4% 2.7%

14 GROUP 1: DIFFERENCES IN HB CONCENTRATION BY CRC LOCALIZATION AND STAGE BOTH SEX Round 1 (µg Hb/g) Round 3-Round 1 (µg Hb/g) CRC RIGHT COLON (16) LEFT COLON (49) BOTH SEX Round 1 (µg Hb/g) Round 3-Round 1 (µg Hb/g) CRC STAGE I-II (41) STAGE III-IV (28)

15 GROUP 2: DIFFERENCES IN HB CONCENTRATION BETWEEN SUCESSIVE AND PREVIOUS ROUND BY LESION BOTH SEX Round 1 (µg Hb/g) Round 2-Round 1 (µg Hb/g) LESIONS IN CRC ROUND 2 (417) AA (3,260) AN (3,677) LRA (1,799) NO LESIONS IN ROUND 2 (171,175) < < < < < < < <

16 GROUP 2: DIFFERENCES IN HB CONCENTRATION BETWEEN SUCESSIVE AND PREVIOUS ROUND BY LESION AND SEX WOMEN Round 1 (µg Hb/g) Round 2-Round 1 (µg Hb/g) LESIONS IN ROUND 2 CRC (147) < <0.001 AA (1,017) AN (1,164) NO LESIONS IN ROUND 2 (94,986) < < < <0.001 LRA (700) < < MEN Round 1 (µg Hb/g) Round 2-Round 1 (µg Hb/g) LESIONS IN ROUND 2 NO LESIONS IN ROUND 2 (76,189) CRC (270) < <0.001 AA (2,228) AN (2,498) LRA (1,099) < < < < < <

17 GROUP 2: HB CONCENTRATION BY RANGES IN FIRST ROUND P< BOTH SEX HB (µg Hb/g) IN ROUND LESION IN CRC (417) 66.4% 14.9% 18.7% ROUND 2 AA (3,240) 66.5% 15.1% 18.4% AN (3,657) 66.5% 15.1% 18.4% LR (1,798) 80.1% 10.5% 9.5% NO LESION ROUND 2 (169,782) 93.9% 3.8% 2.3% P< P< WOMEN HB (µg Hb/g) IN ROUND 1 LESION IN ROUND CRC (147) 70.7% 12.9% 16.3% AA (1,019) 69.4% 13.0% 17.7% AN (1,166) 69.6% 13.0% 17.5% LR (711) 81.2% 11.3% 7.65% NO LESION IN ROUND 2 (94,920) 94.5% 3.6% 2.0% MEN HB (µg Hb/g) IN ROUND LESION IN ROUND 2 CRC (270) 64.1% 15.9% 20.0% AA (2,234) 65.6% 16.7% 17.8% AN (2,504) 65.4% 16.6% 18.0% LR (1,103) 79.1% 9.6% 11.3% NO LESION IN ROUND 2 (76,139) 92.7% 4.5% 2.8%

18 GROUP 2: DIFFERENCES IN HB CONCENTRATION BY CRC LOCALIZATION AND STAGE Round 1 (µg Hb/g) Round 2-Round 1 (µg Hb/g) BOTH SEX CRC RIGHT COLON (86) LEFT COLON (273) BOTH SEX Round 1 (µg Hb/g) Round 2-Round 1 (µg Hb/g) CRC STAGE I-II (252) STAGE III-IV (115)

19 MESSAGE TO TAKE HOME There is no association between previous concentration of Hb and lesion detected in successive rounds. No special pattern was found that allows us to predict the development of Advanced Neoplasia after a negative result. The OR prediction found even their statistical significance in most cases has no clinical relevance No relevant differences were found by sex, age group, CRC stage and localization Intermittent bleeding could be the most important pattern Participation in screening is the most important key to detect lesions Previous bleeding (over 10µ Hb/g faeces) should be carefully considered In order to balance benefits and risks in Screening Programmes

Haemoglobin level at previous negative FIT and risk of neoplasia at subsequent screening rounds. Carlo SENORE

Haemoglobin level at previous negative FIT and risk of neoplasia at subsequent screening rounds. Carlo SENORE Haemoglobin level at previous negative FIT and risk of neoplasia at subsequent screening rounds Carlo SENORE Possible conflicts of interest None related to the presentation Carlo Senore AIMS To estimate

More information

WEO CRC SC Meeting. Vienna, Austria October 14, 2016

WEO CRC SC Meeting. Vienna, Austria October 14, 2016 WEO CRC SC Meeting Vienna, Austria October 14, 216 Possibleconflictsofinterest The Bowel Health Service receives material support from Eiken Chemical Company. Erin Symonds FIT positivity rate is highest

More information

Faecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients

Faecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients Faecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients Caroline Addison NE BCSP Hub Director and Consultant Clinical Scientist What is FIT Type of Faecal Occult Blood test Designed

More information

Friday, 23 October 2015: 10:15 12:00 * * * * *

Friday, 23 October 2015: 10:15 12:00 * * * * * Barcelona 2015 8 th Meeting of the Expert Working Group (EWG) FIT for Screening Expert Working Group (EWG) founding members: Friday, 23 October 2015: 10:15 12:00 MEETING REPORT * * * * * Jim Allison, University

More information

Screening for GI Cancer Past Present and Future. Prof. Bob Steele University of Dundee

Screening for GI Cancer Past Present and Future. Prof. Bob Steele University of Dundee Screening for GI Cancer Past Present and Future Prof. Bob Steele University of Dundee Worldwide Cancer Incidence Rates UK Cancer Incidence Rates Screening The detection of disease in asymptomatic subjects

More information

Risk scoring incorporating FIT in triage of symptomatic patients

Risk scoring incorporating FIT in triage of symptomatic patients Risk scoring incorporating FIT in triage of symptomatic patients Centre for Research into Cancer Prevention and Screening University of Dundee Scotland Possible conflicts of interest None Background Symptoms

More information

Practical challenges in establishing and running the Czech national colorectal cancer screening programme

Practical challenges in establishing and running the Czech national colorectal cancer screening programme Ústřední vojenská nemocnice - Vojenská fakultní nemocnice Praha 1. lékařská fakulta Univerzity Karlovy Interní klinika Practical challenges in establishing and running the Czech national colorectal cancer

More information

Comparison of FIT performance in screening programs. Carlo Senore

Comparison of FIT performance in screening programs. Carlo Senore Comparison of FIT performance in screening programs Possible conflicts of interest None related to the presentation Background Several FIT kits are now available Various FIT brands use a variety of sampling

More information

Friday, 17 October 2014: 08:30 11:30 * * * * *

Friday, 17 October 2014: 08:30 11:30 * * * * * Vienna 2014 6 th Meeting of the Expert Working Group (EWG) FIT for Screening Expert Working Group (EWG) founding members: Friday, 17 October 2014: 08:30 11:30 MEETING REPORT * * * * * Jim Allison, University

More information

Measuring performance and quality indicators of CRC screening

Measuring performance and quality indicators of CRC screening Measuring performance and quality indicators of CRC screening Ondřej MÁJEK Institute of Biostatistics and Analyses, Masaryk University Institute of Biostatistics and Analyses, Masaryk University, Brno

More information

Global colorectal cancer screening appropriate or practical? Graeme P Young, Flinders University WCC, Melbourne

Global colorectal cancer screening appropriate or practical? Graeme P Young, Flinders University WCC, Melbourne Global colorectal cancer screening appropriate or practical? Graeme P Young, Flinders University. 2014 WCC, Melbourne Outline WHO criteria to justify screening Appropriateness: Global variation in incidence

More information

Friday, 15 May 2015: 10:00 12:00 * * * * *

Friday, 15 May 2015: 10:00 12:00 * * * * * Washington 2015 7 th Meeting of the Expert Working Group (EWG) FIT for Screening Friday, 15 May 2015: 10:00 12:00 MEETING REPORT * * * * * Expert Working Group (EWG) founding members: Jim Allison, University

More information

NHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report.

NHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report. NHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report. Sue Moss, Christopher Mathews Centre for Cancer Prevention, Wolfson Institute, Queen Mary University

More information

Implementing of Population-based FOBT Screening

Implementing of Population-based FOBT Screening Implementing of Population-based FOBT Screening gfobt to FIT Experience from England Prof Stephen P. Halloran Guaiac FOBt Haem 2H 2 O 2 = 2H 2 0 + O 2 Oxidised guaiaconic acid is blue Biennial Bowel Cancer

More information

The Dutch bowel cancer screening program Relevant lessions for Ontario

The Dutch bowel cancer screening program Relevant lessions for Ontario The Dutch bowel cancer screening program Relevant lessions for Ontario Ernst J Kuipers Erasmus MC University Medical Center Rotterdam - The Netherlands 1 Ismar Boas (1858 1938) Colorectal cancer screening

More information

Colorectal cancer screening in England

Colorectal cancer screening in England Colorectal cancer screening in England critical analysis Prof Stephen P. Halloran Participation Rate 57% All Screens (1.9% +ve) 52% Prevalent 1 st Screen (age 60 years) 36% Prevalent Screen (2.2% +ve)

More information

Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer

Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer David A. Lieberman, 1 Douglas K. Rex, 2 Sidney J. Winawer,

More information

A TEST FOR COLORECTAL CANCER THAT IS 92% SENSITIVE AND NON-INVASIVE. Stool DNA test

A TEST FOR COLORECTAL CANCER THAT IS 92% SENSITIVE AND NON-INVASIVE. Stool DNA test A TEST FOR COLORECTAL CANCER THAT IS 92% SENSITIVE AND NON-INVASIVE Stool DNA test THE NEW NON-INVASIVE SCREENING TEST FOR COLORECTAL CANCER Sensitive Clinically proven 1 Easy to use FDA approved COLOGUARD

More information

Bowel cancer screening and prevention

Bowel cancer screening and prevention Bowel cancer screening and prevention Cancer Incidence and Mortality Victoria 2012 Number 6000 5000 4000 3000 2000 Incidences = 29,387 Mortality = 10,780 Incidence Mortality 1000 0 Prostate Breast Bowel

More information

WEO CRC SC Meeting. Barcelona, Spain October 23, 2015

WEO CRC SC Meeting. Barcelona, Spain October 23, 2015 WEO CRC SC Meeting Barcelona, Spain October 23, 2015 Identification of serrated polyposis syndrome in the context of population-based CRC screening programs Evelien Dekker Academic Medical Center Amsterdam,

More information

Cost-effectiveness of adenoma surveillance - the Dutch guidelines -

Cost-effectiveness of adenoma surveillance - the Dutch guidelines - Cost-effectiveness of adenoma surveillance - the Dutch guidelines - WEO working group adenoma surveillance 20 May, 2016 Iris Lansdorp-Vogelaar, PhD On behalf of the SAP study-group Introduction Adenoma

More information

Measure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care

Measure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care Measure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: The percentage

More information

Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care

Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:

More information

Prof Stephen P. Halloran. Update on the NHS Bowel Cancer Screening Programme Focus on BS & FIT

Prof Stephen P. Halloran. Update on the NHS Bowel Cancer Screening Programme Focus on BS & FIT Prof Stephen P. Halloran Update on the NHS Bowel Cancer Screening Programme Focus on BS & FIT World Top 20 Cancers Men Incidence & Mortality (2012) Women World Colorectal Cancer 3 rd commonest cancer 4

More information

Challenges for Colorectal Cancer Screening

Challenges for Colorectal Cancer Screening Challenges for Colorectal Cancer Screening a Biomarker with No Standards! Prof. Emeritus Stephen P. Halloran University of Surrey W. Europe Top 20 Cancers Men Incidence & Mortality (2012) Women World -

More information

Bowel Cancer Screening Exploiting science brings better medicine

Bowel Cancer Screening Exploiting science brings better medicine Camberley & District Bowel Cancer Screening Exploiting science brings better medicine Prof Stephen P. Halloran World - All Cancers Men Incidence & Mortality (2012) Women Incidence Mortality GLOBOCAN 2012

More information

FIT Overview. Objectives 6/23/2014

FIT Overview. Objectives 6/23/2014 ADDS 2014: Plenary 2 FIT Update Clarence Wong, MD FRCPC Associate Professor of Medicine, University of Alberta Provincial Medical Lead, Alberta Colorectal Cancer Screening Program 1 Objectives After this

More information

Performance of Colorectal cancer screening in the European Union Member States Data from the second European screening report

Performance of Colorectal cancer screening in the European Union Member States Data from the second European screening report Performance of Colorectal cancer screening in the European Union Member States Data from the second European screening report 1 Basu P 2, Anttila A 3, Ponti A 1, Tomatis M 1, Vale DB 4, Ronco G 1, Soerjomataram

More information

IARC Handbook Volume 17: Colorectal Cancer Screening. Béatrice Lauby-Secretan, PhD on behalf of the IARC Working Group for Volume 17

IARC Handbook Volume 17: Colorectal Cancer Screening. Béatrice Lauby-Secretan, PhD on behalf of the IARC Working Group for Volume 17 IARC Handbook Volume 17: Colorectal Cancer Screening Béatrice Lauby-Secretan, PhD on behalf of the IARC Working Group for Volume 17 IARC Handbooks of Cancer Prevention An important part of cancer prevention

More information

FIT - A Tale of Two Settings. Callum G Fraser Centre for Research into Cancer Prevention and Screening University of Dundee Scotland

FIT - A Tale of Two Settings. Callum G Fraser Centre for Research into Cancer Prevention and Screening University of Dundee Scotland FIT - A Tale of Two Settings Callum G Fraser Centre for Research into Cancer Prevention and Screening University of Dundee Scotland Possible Conflicts of Interest Consultant: Kyowa, Tokyo, Japan Consultant:

More information

An Update on the Bowel Cancer Screening Programme. Natasha Djedovic, London Hub Director 17 th September 2018

An Update on the Bowel Cancer Screening Programme. Natasha Djedovic, London Hub Director 17 th September 2018 An Update on the Bowel Cancer Screening Programme Natasha Djedovic, London Hub Director 17 th September 2018 NHS Bowel Cancer Screening Programme 2006: 60-69 yr old men & women offered guaiac Faecal Occult

More information

FREQUENTLY ASKED QUESTIONS

FREQUENTLY ASKED QUESTIONS FREQUENTLY ASKED QUESTIONS What is CRC? CRC (CRC) is cancer of the large intestine (colon), the lower part of the digestive system. Rectal cancer is cancer of the last several inches of the colon. Together,

More information

Efficacy, effectiveness, quality: sources of data

Efficacy, effectiveness, quality: sources of data Efficacy, effectiveness, quality: sources of data Ondřej MÁJEK Institute of Biostatistics and Analyses, Masaryk University Institute of Biostatistics and Analyses, Masaryk University, Brno Key Questions

More information

Why FIT (Faecal Immunochemical Test) is the best biomarker for CRC screening

Why FIT (Faecal Immunochemical Test) is the best biomarker for CRC screening Why FIT (Faecal Immunochemical Test) is the best biomarker for CRC screening Prof. Stephen Halloran Royal Surrey County Hospital NHS Cancer Screening Programme University of Surrey gfobt Guaiacum Officinale

More information

Bowel Cancer Screening

Bowel Cancer Screening Bowel Cancer Screening Dr John Hancock FRCP Consultant Gastroenterologist University Hospital of North Tees Outline Background Current bowel cancer screening programme Tees Screening Centre Future Flexi

More information

Optimizing implementation of fecal immunochemical testing in Ontario: A randomized controlled trial

Optimizing implementation of fecal immunochemical testing in Ontario: A randomized controlled trial Optimizing implementation of fecal immunochemical testing in Ontario: A randomized controlled trial J. Tinmouth, N.N. Baxter, L.F. Paszat, E. Randell, M. Serenity, R. Sutradhar, L. Rabeneck Conflicts of

More information

Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?

Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex? Arana-Arri et al. BMC Cancer (2017) 17:577 DOI 10.1186/s12885-017-3555-3 RESEARCH ARTICLE Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin

More information

Colorectal cancer screening

Colorectal cancer screening 26 Colorectal cancer screening BETHAN GRAF AND JOHN MARTIN Colorectal cancer is theoretically a preventable disease and is ideally suited to a population screening programme, as there is a long premalignant

More information

COLORECTAL CANCER: A CHALLENGE FOR HEALTHY LIFESTYLE, SCREENING AND PROPER CARE

COLORECTAL CANCER: A CHALLENGE FOR HEALTHY LIFESTYLE, SCREENING AND PROPER CARE COLORECTAL CANCER: A CHALLENGE FOR HEALTHY LIFESTYLE, SCREENING AND PROPER CARE Brno, 29 May 2015: For the fourth time in a row, the second largest city of the Czech Republic will host the European Colorectal

More information

North West London Pathology. Faecal Occult Blood testing. Mrs Sophie Barnes FRCPath Consultant Clinical Scientist

North West London Pathology. Faecal Occult Blood testing. Mrs Sophie Barnes FRCPath Consultant Clinical Scientist Faecal Occult Blood testing Mrs Sophie Barnes FRCPath Consultant Clinical Scientist Learning objectives Background Guidelines for colorectal cancer detection Tests available to detect occult blood in faeces

More information

Screening and Primary prevention of Colorectal Cancer: a Review of sex-specific and site-specific differences

Screening and Primary prevention of Colorectal Cancer: a Review of sex-specific and site-specific differences Original Article Screening and Primary prevention of Colorectal Cancer: a Review of sex-specific and site-specific differences J Med Screen 20(3) 125 148! The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalspermissions.nav

More information

Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model

Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model Idigoras et al. BMC Public Health (2018)18:78 DOI 10.1186/s12889-017-4639-3 RESEARCH ARTICLE Open Access Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness

More information

University of Dundee. Published in: Journal of Medical Screening DOI: / Publication date: 2016

University of Dundee. Published in: Journal of Medical Screening DOI: / Publication date: 2016 University of Dundee Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited Digby, Jayne; Fraser, Callum G.; Carey, Francis A.; Lang,

More information

Colonoscopy Quality Data 2017

Colonoscopy Quality Data 2017 Colonoscopy Quality Data Introduction Colorectal cancer is the second leading cause of cancer related deaths in the United States, in men and women combined. According to the American Cancer Society, in

More information

Quantitative immunochemical tests: evidence on accuracy and implementation considerations in the Czech MUDr.. Petr Kocna, CSc.

Quantitative immunochemical tests: evidence on accuracy and implementation considerations in the Czech MUDr.. Petr Kocna, CSc. Quantitative immunochemical tests: evidence on accuracy and implementation considerations in the Czech MUDr.. Petr Kocna, CSc. European Digestive Cancer Days, Prague - 26. September 2017 QUANTITATIVE FIT

More information

Friday, 20 May 2016: 10:15 12:00 MEETING REPORT * * * * *

Friday, 20 May 2016: 10:15 12:00 MEETING REPORT * * * * * San Diego 2016 9 th Meeting of the Expert Working Group (EWG) FIT for Screening Expert Working Group (EWG) founding members: Friday, 20 May 2016: 10:15 12:00 MEETING REPORT * * * * * Jim Allison, University

More information

EU Guidelines for quality assurance in organization, implementation and monitoring of colorectal cancer screening programme. Jožica Maučec Zakotnik

EU Guidelines for quality assurance in organization, implementation and monitoring of colorectal cancer screening programme. Jožica Maučec Zakotnik EU Guidelines for quality assurance in organization, implementation and monitoring of colorectal cancer screening programme Jožica Maučec Zakotnik EU guidelines Luxembourg 2010 EU guidelines - chapters

More information

Czech CRC screening program at the point of switch to the population based design

Czech CRC screening program at the point of switch to the population based design Military University Hospital First Medical Faculty of Charles University Department of Gastroenterology Czech CRC screening program at the point of switch to the population based design M. Zavoral, S.

More information

Colorectal cancer screening: strategies to select populations with moderate risk for disease

Colorectal cancer screening: strategies to select populations with moderate risk for disease 1130-0108/2009/101/12/855-860 REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS Copyright 2009 ARÁN EDICIONES, S. L. REV ESP ENFERM DIG (Madrid) Vol. 101. N. 12, pp. 855-860, 2009 Colorectal cancer screening:

More information

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work. Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical

More information

Results from 2.6 million invitations between : 54% overall uptake (von Wagner et al., 2011)

Results from 2.6 million invitations between : 54% overall uptake (von Wagner et al., 2011) TRICCS: Text-message Reminders in Colorectal Cancer Screening Research Department of Behavioural Science and Health University College London Christian von Wagner (c.wagner@ucl.ac.uk ) Background Colorectal

More information

Objectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background

Objectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background Colorectal Cancer Screening Payam Afshar, MS, MD Kaiser Permanente, San Diego Objectives Colorectal cancer background Colorectal cancer screening populations Colorectal cancer screening modalities Colonoscopy

More information

Quality of and compliance with colonoscopy in Lynch Syndrome surveillance: are we getting it right?

Quality of and compliance with colonoscopy in Lynch Syndrome surveillance: are we getting it right? Quality of and compliance with colonoscopy in Lynch Syndrome surveillance: are we getting it right? Hartery K 1, Sukha A 1, Thomas-Gibson S 1, Thomas H 1,2, Latchford A 1,2. 1 Wolfson Endoscopy Unit, St.

More information

Performance targets for lesion detection in surveillance

Performance targets for lesion detection in surveillance Performance targets for lesion detection in surveillance WEO CRC Meeting 2018, Washington DC Uri Ladabaum, M.D., M.S. Professor of Medicine; Director, GI Cancer Prevention Division of Gastroenterology

More information

COLON CANCER SCREENING: AN UPDATE

COLON CANCER SCREENING: AN UPDATE Overview COLON CANCER SCREENING: AN UPDATE Siddharth Verma, DO, JD Rutgers New Jersey Medical School Background Screening Updates in Specific Populations African Americans CRC in the younger age USPSTF

More information

Fecal immunochemical testing results and characteristics of colonic lesions

Fecal immunochemical testing results and characteristics of colonic lesions Original article 111 Fecal immunochemical testing results and characteristics of colonic lesions Authors Sascha C. van Doorn 1, Inge Stegeman 2, An K. Stroobants 3, Marco W. Mundt 4, Thomas R. de Wijkerslooth

More information

Early detection and screening for colorectal neoplasia

Early detection and screening for colorectal neoplasia Early detection and screening for colorectal neoplasia Robert S. Bresalier Department of Gastroenterology, Hepatology and Nutrition. The University of Texas. MD Anderson Cancer Center. Houston, Texas U.S.A.

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Preventive Care 2019 COLLECTION TYPE: MIPS CLINICAL QUALITY

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #185 (NQF 0659): Colonoscopy Interval for Patients with a History of Adenomatous Polyps Avoidance of Inappropriate Use National Quality Strategy Domain: Communication and Care Coordination 2018

More information

What I ll discuss. Head to Head Comparisons of Different FITs. What makes a FIT good? What makes a good FIT? Good performance

What I ll discuss. Head to Head Comparisons of Different FITs. What makes a FIT good? What makes a good FIT? Good performance WEO SC EWG FIT for Screening Head to Head Comparisons of Different FITs Thomas F. Imperiale, MD Indiana University Medical Center WEO SC DDW San Diego, CA May 20, 2016 What I ll discuss Technical / clinical

More information

Diagnostics guidance Published: 26 July 2017 nice.org.uk/guidance/dg30

Diagnostics guidance Published: 26 July 2017 nice.org.uk/guidance/dg30 Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care Diagnostics guidance Published: 26 July 2017 nice.org.uk/guidance/dg30 NICE 2018. All rights reserved. Subject

More information

Colorectal Cancer Prevention Hospital Universitário São Paulo University

Colorectal Cancer Prevention Hospital Universitário São Paulo University Colorectal Cancer Prevention Hospital Universitário São Paulo University GENERAL STRATEGY AND RESULTS Dr Luis Masúo Maruta Dr. Marcelo Rodrigues Borba Hospital Universitário São Paulo University Hospital

More information

C olorectal cancer (CRC) is one of the leading causes of

C olorectal cancer (CRC) is one of the leading causes of 1329 COLON Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure

More information

COLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION.

COLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION. The West London Medical Journal 2009 Vol No 1 pp 23-31 COLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION. Competing interests: None declared ABSTRACT Sarah

More information

Colorectal Cancer Screening and Surveillance

Colorectal Cancer Screening and Surveillance 1 Colorectal Cancer Screening and Surveillance Jeffrey Lee MD, MAS Assistant Clinical Professor of Medicine University of California, San Francisco jeff.lee@ucsf.edu Objectives Review the various colorectal

More information

Population-based colorectal cancer screening by fecal immunochemical testing over multiple rounds van der Vlugt, M.

Population-based colorectal cancer screening by fecal immunochemical testing over multiple rounds van der Vlugt, M. UvA-DARE (Digital Academic Repository) Population-based colorectal cancer screening by fecal immunochemical testing over multiple rounds van der Vlugt, M. Link to publication Citation for published version

More information

Dr Katie Elliott CRUK strategic GP Macmillan GP with NE &C Learning disability Network Assistant Clinical Lead Northern Cancer Alliance

Dr Katie Elliott CRUK strategic GP Macmillan GP with NE &C Learning disability Network Assistant Clinical Lead Northern Cancer Alliance FIT for symptomatic patients Dr Katie Elliott CRUK strategic GP Macmillan GP with NE &C Learning disability Network Assistant Clinical Lead Northern Cancer Alliance AIMS Review National advice Consider

More information

Sarvenaz Moosavi, 1 Robert Enns, 1 Laura Gentile, 2 Lovedeep Gondara, 2 Colleen McGahan, 2 and Jennifer Telford Introduction

Sarvenaz Moosavi, 1 Robert Enns, 1 Laura Gentile, 2 Lovedeep Gondara, 2 Colleen McGahan, 2 and Jennifer Telford Introduction Canadian Gastroenterology and Hepatology Volume 2016, Article ID 5914048, 5 pages http://dx.doi.org/10.1155/2016/5914048 Research Article Comparison of One versus Two Fecal Immunochemical Tests in the

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process Measure. #185 (NQF 0659): Colonoscopy Interval for Patients with a History of Adenomatous Polyps Avoidance of Inappropriate Use National Quality Strategy Domain: Communication and Care Coordination 2017

More information

Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests

Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests O R I G I N A L A R T I C L E Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests L.G.M. van Rossum 1*, A.F. van Rijn 2, I.P. van Munster 3, J.B.M.J. Jansen 1, P.

More information

Screening di Popolazione. del Cancro Colorettale. C. Hassan

Screening di Popolazione. del Cancro Colorettale. C. Hassan Screening di Popolazione del Cancro Colorettale C. Hassan The Present 1. Organized screening program - Active invitation (less inequality) - Rapid coverage of the target population (2 yrs) - Quality Assurance

More information

Primary care at the forefront of colorectal cancer screening

Primary care at the forefront of colorectal cancer screening Primary care at the forefront of colorectal cancer screening Presentation by Bohumil Seifert Department of General Practice, 1st Faculy of Medicine, Charles University in Prague 04/05/2012 Introduction

More information

Pathology in Slovenian CRC screening programme:

Pathology in Slovenian CRC screening programme: Pathology in Slovenian CRC screening programme: Findings, organisation and quality assurance Snježana Frković Grazio University Medical Center Ljubljana, Slovenia Slovenia s population: 2 million Incidence

More information

Time to Colonoscopy and Risk of Colorectal Cancer in Patients With Positive Results From Fecal Immunochemical Tests

Time to Colonoscopy and Risk of Colorectal Cancer in Patients With Positive Results From Fecal Immunochemical Tests Accepted Manuscript Time to Colonoscopy and Risk of Colorectal Cancer in Patients With Positive Results From Fecal Immunochemical Tests Yi-Chia Lee, MD, PhD, Jean Ching-Yuan Fann, PhD, Tsung-Hsien Chiang,

More information

Socioeconomic and ethnic inequalities in organized colorectal cancer screening participation

Socioeconomic and ethnic inequalities in organized colorectal cancer screening participation Socioeconomic and ethnic inequalities in organized colorectal cancer screening participation C.M. de Klerk 1, S. Gupta 2, E. Dekker 1, M.L. Essink-Bot 3 1) Department of Gastroenterology and Hepatology,

More information

Frequency of Diagnosis of Colorectal Cancer with Double Contrast Barium Enema

Frequency of Diagnosis of Colorectal Cancer with Double Contrast Barium Enema Bahrain Medical Bulletin, Vol.24, No.3, September 2002 Frequency of Diagnosis of Colorectal Cancer with Double Contrast Barium Enema Najeeb S Jamsheer, MD, FRCR* Neelam. Malik, MD, MNAMS** Objective: To

More information

Post-polypectomy follow-up after. removal of colorectal neoplasia

Post-polypectomy follow-up after. removal of colorectal neoplasia Post-polypectomy follow-up after removal of colorectal neoplasia Post-polypectomy endoscopic surveillance For each type of polyp BENEFIT 1. What is the risk of CRC/Adv. Neo. (AN) w/out surveillance?

More information

11/9/2015 OUTLINE. Quality Indicators for the Doctor Performing Screening Colonoscopy: What you should expect from your Endoscopist

11/9/2015 OUTLINE. Quality Indicators for the Doctor Performing Screening Colonoscopy: What you should expect from your Endoscopist Quality Indicators for the Doctor Performing Screening Colonoscopy: What you should expect from your Endoscopist Anil K Sharma MD FACP Professor of Clinical Medicine, University of Rochester Chief of Gastroenterology,

More information

Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines

Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions

More information

The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an open-label, randomized controlled trial

The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an open-label, randomized controlled trial Page1 of 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an

More information

Bowel cancer risk in the under 50s. Greg Rubin Professor of General Practice and Primary Care

Bowel cancer risk in the under 50s. Greg Rubin Professor of General Practice and Primary Care Bowel cancer risk in the under 50s Greg Rubin Professor of General Practice and Primary Care Prevalence of GI problems in the consulting population Thompson et al, Gut 2000 Number of patients % of patients

More information

Screening for colorectal cancer. Stuart Taylor Consultant Radiologist University College Hospital

Screening for colorectal cancer. Stuart Taylor Consultant Radiologist University College Hospital Screening for colorectal cancer Stuart Taylor Consultant Radiologist University College Hospital Topics Rationale for screening Screening methods CTC (+CAD) as a screening tool Epidemiology 943,000 cases

More information

Financial Disclosers

Financial Disclosers Slide 1 Colorectal Cancer Screening Jason Hemming, MD NESGNA November 15, 2014 Slide 2 Bio Slide 3 Financial Disclosers I have no actual or potential conflict of interest relation to this presentation

More information

Debate: General surveillance/screening for colon cancer in a resource constrained environment is imperative

Debate: General surveillance/screening for colon cancer in a resource constrained environment is imperative Debate: General surveillance/screening for colon cancer in a resource constrained environment is imperative Dr. Meryl Oyomno Department of surgery, University of Pretoria INTRODUCTION Screening is the

More information

Colonoscopy Quality Data

Colonoscopy Quality Data Colonoscopy Quality Data www.dhsgi.com Introduction Colorectal cancer is the second leading cause of cancer related deaths in the United States, in men and women combined. In 2016, there are expected to

More information

THE NEW ZEALAND MEDICAL JOURNAL

THE NEW ZEALAND MEDICAL JOURNAL THE NEW ZEALAND MEDICAL JOURNAL Journal of the New Zealand Medical Association Colonoscopy requirements of population screening for colorectal cancer in New Zealand Terri Green, Ann Richardson, Susan Parry

More information

Colorectal Cancer Screening. Paul Berg MD

Colorectal Cancer Screening. Paul Berg MD Colorectal Cancer Screening Paul Berg MD What is clinical integration? AMA Definition The means to facilitate the coordination of patient care across conditions, providers, settings, and time in order

More information

CENTERS FOR DISEASE CONTROL AND PREVENTION CENTERS FOR DISEASE CONTROL AND PREVENTION. Incidence Male. Incidence Female.

CENTERS FOR DISEASE CONTROL AND PREVENTION CENTERS FOR DISEASE CONTROL AND PREVENTION. Incidence Male. Incidence Female. A Call to Action: Prevention and Early Detection of Colorectal Cancer (CRC) 5 Key Messages Screening reduces mortality from CRC All persons aged 50 years and older should begin regular screening High-risk

More information

Bowel Cancer Prevention and Screening. Harriet Wynne, Cancer Council Victoria

Bowel Cancer Prevention and Screening. Harriet Wynne, Cancer Council Victoria Bowel Cancer Prevention and Screening Harriet Wynne, Cancer Council Victoria New cases and deaths for the Victoria population in 2013 Thursfield V, et al. Cancer in Victoria: Statistics & trends 2013.

More information

Rx Only. Detecting Cancer In Blood.

Rx Only. Detecting Cancer In Blood. Epi procolon is an FDA-approved blood test for colorectal cancer screening for patients who are unwilling or unable to be screened by recommended methods. Rx Only Intended Use, Contraindications, Warnings,

More information

The choice of methods for Colorectal Cancer Screening; The Dutch experience

The choice of methods for Colorectal Cancer Screening; The Dutch experience The choice of methods for Colorectal Cancer Screening; The Dutch experience Monique van Leerdam, Gastroenterologist, NKI-AVL, Amsterdam The Netherlands Colorectal cancer CRC 2 nd cause of cancer related

More information

PATIENT BROCHURE. 441 Charmany Dr 1 Madison WI, RX Only

PATIENT BROCHURE. 441 Charmany Dr 1 Madison WI, RX Only PATIENT BROCHURE 441 Charmany Dr 1 Madison WI, 53719 844-870- 8870 Cologuard colorectal cancer screening test is a registered trademark of Exact Sciences Corporation. Indications for Use Cologuard is intended

More information

Adding family history of colorectal cancer to the FIT-based screening program in a Dutch screening population sample

Adding family history of colorectal cancer to the FIT-based screening program in a Dutch screening population sample Adding family history of colorectal cancer to the FIT-based screening program in a Dutch screening population sample Victorine H. Roos, Frank G.J. Kallenberg, Manon van der Vlugt, Evelien J.C. Bongers,

More information

How to Screen a patient with a Family History of Adenoma(s)

How to Screen a patient with a Family History of Adenoma(s) How to Screen a patient with a Family History of Adenoma(s) CDDW Banff 3-5-17 David Lieberman MD Chief, Division of Gastroenterology and Hepatology Oregon Health and Science University Disclosures 2016

More information

Symptom or faecal immunochemical test based referral criteria for colorectal cancer detection in symptomatic patients: a diagnostic tests study

Symptom or faecal immunochemical test based referral criteria for colorectal cancer detection in symptomatic patients: a diagnostic tests study Herrero et al. BMC Gastroenterology (2018) 18:155 https://doi.org/10.1186/s12876-018-0887-7 RESEARCH ARTICLE Symptom or faecal immunochemical test based referral criteria for colorectal cancer detection

More information

Risk assessment tools for the symptomatic population Graham Radford-Smith Department of Gastroenterology and Hepatology Royal Brisbane and Women s

Risk assessment tools for the symptomatic population Graham Radford-Smith Department of Gastroenterology and Hepatology Royal Brisbane and Women s Risk assessment tools for the symptomatic population Graham Radford-Smith Department of Gastroenterology and Hepatology Royal Brisbane and Women s Hospital GI inflammation IBD Group QIMR Berghofer Medical

More information

Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery

Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation

More information

C olorectal cancer (CRC) is the second most common

C olorectal cancer (CRC) is the second most common CANCER Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial J H Scholefield, S Moss, F Sufi, C M Mangham, J D Hardcastle... See end of

More information

T. Rubeca 1, S. Rapi 2, M. Confortini 1, M. Brogioni 2, G. Grazzini 1, M. Zappa 1, D. Puliti 1, G. Castiglione 1, S. Ciatto 1

T. Rubeca 1, S. Rapi 2, M. Confortini 1, M. Brogioni 2, G. Grazzini 1, M. Zappa 1, D. Puliti 1, G. Castiglione 1, S. Ciatto 1 The International Journal of Biological Markers, Vol. 21 no. 3, pp. 157-161 2006 Wichtig Editore Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold

More information

Lessons learnt from cancer screening programmes as an example for establishing the Czech National Coordination Centre

Lessons learnt from cancer screening programmes as an example for establishing the Czech National Coordination Centre Czech National Coordination Centre for Prevention of Serious Diseases CZ.03.2.63/0.0/0.0/15_039/0006904 Lessons learnt from cancer screening programmes as an example for establishing the Czech National

More information